4D Molecular Therapeutics Newsroom

4D Molecular Therapeutics to Focus Pipeline on Wet AMD, Cystic Fibrosis Drug Candidates

MT NewswiresJan 10 08:53 ET

4DMT Extends Cash Runway To 2028 With $506M, Plans Phase 3 Trials For 4FRONT-1 & 4FRONT-2 In Wet AMD, Develops Early-Stage DME And CF, Explores Partnerships And Strategic Financing

BenzingaJan 10 08:03 ET

Express News | 4D Molecular Therapeutics Inc: Cash Runway Extended Under Updated Operating Plan Expected to Fund Operations Into 2028

ReutersJan 10 08:01 ET

Express News | 4D Molecular Therapeutics Inc: Primary Endpoint 52-Week Topline Data for Both 4Front-1 and 4Front-2 Expected in H2 2027

ReutersJan 10 08:01 ET

Express News | 4D Molecular Therapeutics Inc - 4D-150 Well Tolerated With No Intraocular Inflammation Observed

ReutersJan 10 08:01 ET

Express News | 4Dmt Announces Positive Interim Data From 4D-150 Spectra Clinical Trial in Dme and Alignment With FDA on Registrational Path

ReutersJan 10 08:00 ET

4DMT Announces Positive Interim Data From 4D-150 SPECTRA Clinical Trial in DME and Alignment With FDA on Registrational Path

GlobeNewswireJan 10 08:00 ET

Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday

BenzingaDec 18, 2024 10:20 ET

4D Molecular Therapeutics Analyst Ratings

BenzingaDec 18, 2024 07:49 ET · Ratings

BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $46

Moomoo NewsDec 18, 2024 07:31 ET · Ratings

Express News | 4D Molecular Therapeutics Inc : BofA Global Research Cuts Price Objective to $46 From $79

ReutersDec 18, 2024 07:16 ET

Express News | 4Dmt Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in Iovs

ReutersDec 16, 2024 08:00 ET

We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth

Simply Wall StNov 27, 2024 06:17 ET

4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now

Yahoo FinanceNov 26, 2024 06:51 ET

4D Molecular Initiated by Morgan Stanley at Underweight

Seeking AlphaNov 21, 2024 13:58 ET

Morgan Stanley Initiates 4D Molecular Therapeutics(FDMT.US) With Sell Rating, Announces Target Price $8

Moomoo NewsNov 21, 2024 05:31 ET · Ratings

4D Molecular Therapeutics' Positive Q3 and Strategic Advances

TipRanksNov 15, 2024 22:53 ET

Chardan Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $39

Moomoo NewsNov 14, 2024 17:32 ET · Ratings

4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesNov 14, 2024 16:54 ET · Ratings

Analyst Expectations For 4D Molecular Therapeutics's Future

BenzingaNov 14, 2024 12:00 ET